Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 12, 2021 Filed Apr 13, 2021 21:23 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 4,800 | $200.00 | $960,000.00 |
DisclosureSEC source: 0001127602-21-013699 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,046 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 21:22 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,500 | $198.47 | $496,175.00 |
DisclosureSEC source: 0001127602-21-013698 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,922 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 15:12 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 1,487 | $196.15 | $291,675.05 |
DisclosureSEC source: 0001127602-21-013306 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,294 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 15:48 UTC |
Sodhi RajwantPresident, SaaS Business
|
SaleResMed Common Stock | 1,500 | $194.14 | $291,210.00 |
DisclosureSEC source: 0001127602-21-012914 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,088 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 22:31 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 1,081 | $185.48 | $200,503.88 |
DisclosureSEC source: 0001127602-21-010864 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 211,371 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 10, 2021 Filed Mar 11, 2021 22:43 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,500 | $185.00 | $462,500.00 |
DisclosureSEC source: 0001127602-21-010277 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,422 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 19:09 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 1,487 | $191.80 | $285,206.60 |
DisclosureSEC source: 0001127602-21-009363 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,781 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 18:16 UTC |
Sodhi RajwantPresident, SaaS Business
|
SaleResMed Common Stock | 1,500 | $194.34 | $291,510.00 |
DisclosureSEC source: 0001127602-21-008609 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,588 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 16:48 UTC |
TAYLOR RONALD RDirector
|
SaleResMed Common Stock | 4,000 | $200.14 | $800,564.40 |
DisclosureSEC source: 0001127602-21-006887 · form4.xml · nonDerivative · entry 1 TAYLOR RONALD R · CIK 0001161920 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,769 F1 · price: This transaction was executed in multiple trades at prices ranging from $200.07 to $200.50. The price reported above reflects the weighted average sale price. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 21:47 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 998 | $200.46 | $200,059.08 |
DisclosureSEC source: 0001127602-21-006245 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 212,452 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 10, 2021 Filed Feb 11, 2021 21:45 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,500 | $201.37 | $503,425.00 |
DisclosureSEC source: 0001127602-21-005251 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,922 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 18:11 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 1,487 | $204.42 | $303,972.54 |
DisclosureSEC source: 0001127602-21-004154 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,268 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 23:59 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 2,400 | $200.18 | $480,436.80 |
DisclosureSEC source: 0001127602-21-003568 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,846 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 18:28 UTC |
Sodhi RajwantPresident, SaaS Business
|
SaleResMed Common Stock | 1,500 | $203.76 | $305,640.00 |
DisclosureSEC source: 0001127602-21-003439 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,088 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 18, 2021 Filed Jan 20, 2021 01:03 UTC |
Leong JustinPresident, Asia Latin America
|
GrantReMed Common Stock | 865 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002068 · form4.xml · nonDerivative · entry 1 Leong Justin · CIK 0001825782 · President, Asia Latin America 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,064 F1 · kind: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on January 18, 2021, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| January 18, 2021 Filed Jan 20, 2021 01:02 UTC |
Sodhi RajwantPresident, SaaS Business
|
GrantResMed Common Stock | 1,913 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002067 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,588 F1 · shares: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on January 18, 2021, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| January 18, 2021 Filed Jan 20, 2021 00:59 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GrantResMed Common Stock | 1,548 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002066 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,755 F1 · shares: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on January 18, 2021, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| January 18, 2021 Filed Jan 20, 2021 00:58 UTC |
Hollingshead JamesPresident, Sleep Business
|
GrantResMed Common Stock | 1,913 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002065 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,246 F1 · shares: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on January 18, 2021, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| January 18, 2021 Filed Jan 20, 2021 00:57 UTC |
Sandercock BrettChief Financial Officer
|
GrantResMed Common Stock | 1,822 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002064 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,422 F1 · shares: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on January 18, 2021, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| January 18, 2021 Filed Jan 20, 2021 00:55 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
GrantResMed Common Stock | 4,099 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002063 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,701 F1 · shares: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on January 18, 2021, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| January 18, 2021 Filed Jan 20, 2021 00:53 UTC |
Farrell Michael J.Chief Executive Officer
|
GrantResMed Common Stock | 7,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002062 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 406,160 F1 · shares: Represents performance-based restricted stock units granted on November 21, 2019. The shares were earned on January 18, 2021, when the compensation committee certified that the performance metrics were met for this portion of the grant. The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 22:24 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 938 | $212.86 | $199,662.68 |
DisclosureSEC source: 0001127602-21-002006 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 213,450 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 21:11 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,500 | $218.70 | $546,750.00 |
DisclosureSEC source: 0001127602-21-001481 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,600 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:52 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 2,400 | $211.09 | $506,613.60 |
DisclosureSEC source: 0001127602-21-000640 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,333 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:50 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 1,487 | $213.24 | $317,087.88 |
DisclosureSEC source: 0001127602-21-000635 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,207 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 17:45 UTC |
Sodhi RajwantPresident, SaaS Business
|
SaleResMed Common Stock | 1,500 | $213.24 | $319,860.00 |
DisclosureSEC source: 0001127602-21-000331 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,675 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 19:58 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 970 | $207.80 | $201,566.00 |
DisclosureSEC source: 0001127602-20-031504 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 214,388 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 17:43 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,500 | $211.06 | $527,650.00 |
DisclosureSEC source: 0001127602-20-031237 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,100 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 17:41 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 1,487 | $208.36 | $309,831.32 |
DisclosureSEC source: 0001127602-20-030668 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,694 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 01, 2020 Filed Dec 2, 2020 00:37 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 2,400 | $210.97 | $506,330.40 |
DisclosureSEC source: 0001127602-20-030251 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,733 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 01, 2020 Filed Dec 2, 2020 22:57 UTC |
Sodhi RajwantPresident, SaaS Business
|
SaleResMed Common Stock | 1,500 | $210.46 | $315,690.00 |
DisclosureSEC source: 0001127602-20-030342 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,175 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 27, 2020 Filed Dec 1, 2020 01:33 UTC |
Gill HarjitDirector
|
Tax withholdingResMed Common Stock | 116 | $212.11 | $24,604.76 |
DisclosureSEC source: 0001127602-20-030148 · form4.xml · nonDerivative · entry 1 Gill Harjit · CIK 0001759311 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,229 F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/21/2019. Read SEC document |
| November 27, 2020 Filed Nov 30, 2020 20:56 UTC |
De Witte JanDirector
|
Tax withholdingReMed Common Stock | 183 | $212.11 | $38,816.13 |
DisclosureSEC source: 0001127602-20-030106 · form4.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,137 F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/21/2019. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 16:50 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
GiftResMed Common Stock | 478 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-029982 · form4.xml · nonDerivative · entry 2 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 215,358 F2 · kind: Gift of shares to Fidelity Charitable, a donor advised fund. Mr. Douglas has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 16:50 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 955 | $211.00 | $201,505.00 |
DisclosureSEC source: 0001127602-20-029982 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 215,836 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 23:01 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 5,000 | $211.00 | $1,055,000.00 |
DisclosureSEC source: 0001127602-20-030034 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,600 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 18:31 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GiftResMed Common Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-029909 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,181 F1 · kind: Gift of shares to The San Diego Foundation, a 501(c)(3) nonprofit organization. Mr. Pendarvis has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 18:31 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 1,176 | $0.00 Strike: $84.98 | $0.00 |
DisclosureSEC source: 0001127602-20-029909 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,519 Underlying: ResMed Common Stock · 1,176 shares Expires 2024-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 18:31 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 1,176 | $84.98 | $99,936.48 |
DisclosureSEC source: 0001127602-20-029909 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2020 Filed Nov 21, 2020 01:19 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
GrantResMed Common Stock Options · Derivative | 7,702 | $0.00 Strike: $211.76 | $0.00 |
DisclosureSEC source: 0001127602-20-029776 · form4.xml · derivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,702 Underlying: ResMed Common Stock · 7,702 shares Expires 2027-11-19 F1 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2021, 2022 and 2023. Read SEC document |
| November 19, 2020 Filed Nov 21, 2020 01:14 UTC |
TAYLOR RONALD RDirector
|
GrantResMed Common Stock | 1,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-029774 · form4.xml · nonDerivative · entry 1 TAYLOR RONALD R · CIK 0001161920 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,769 F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2021, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 19, 2020 Filed Nov 21, 2020 00:57 UTC |
Drexler KarenDirector
|
GrantResMed Common Stock Options · Derivative | 2,265 | $0.00 Strike: $211.76 | $0.00 |
DisclosureSEC source: 0001127602-20-029768 · form4.xml · derivative · entry 2 Drexler Karen · CIK 0001504699 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,265 Underlying: ResMed Common Stock · 2,265 shares Expires 2027-11-19 F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest on the earlier of (i) the first November 11 following the Grant Date, or (ii) the date of the first (1st) annual meeting of stockholders of the Company following the Grant Date. Read SEC document |
| November 19, 2020 Filed Nov 21, 2020 00:57 UTC |
Drexler KarenDirector
|
GrantResMed Common Stock | 594 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-029768 · form4.xml · nonDerivative · entry 1 Drexler Karen · CIK 0001504699 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,981 F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2021, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 19, 2020 Filed Nov 21, 2020 01:12 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
GrantResMed Common Stock Options · Derivative | 20,388 | $0.00 Strike: $211.76 | $0.00 |
DisclosureSEC source: 0001127602-20-029772 · form4.xml · derivative · entry 3 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,388 Underlying: ResMed Common Stock · 20,388 shares Expires 2027-11-19 F1 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2021, 2022 and 2023. Read SEC document |
| November 19, 2020 Filed Nov 21, 2020 00:19 UTC |
SULPIZIO RICHARDDirector
|
GrantResMed Common Stock | 1,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-029763 · form4.xml · nonDerivative · entry 1 SULPIZIO RICHARD · CIK 0001191329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,867 F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2021, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 19, 2020 Filed Nov 21, 2020 00:12 UTC |
Gill HarjitDirector
|
GrantResMed Common Stock | 1,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-029761 · form4.xml · nonDerivative · entry 1 Gill Harjit · CIK 0001759311 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,345 F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2021, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 19, 2020 Filed Nov 21, 2020 00:05 UTC |
Burt CarolDirector
|
GrantResMed Common Stock | 1,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-029757 · form4.xml · nonDerivative · entry 1 Burt Carol · CIK 0001493926 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,914 F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2021, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 19, 2020 Filed Nov 21, 2020 00:08 UTC |
De Witte JanDirector
|
GrantReMed Common Stock | 1,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-029759 · form4.xml · nonDerivative · entry 1 De Witte Jan · CIK 0001776929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,320 F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2021, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 19, 2020 Filed Nov 21, 2020 00:00 UTC |
FARRELL PETER CDirector
|
GrantResMed Common Stock | 1,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-029753 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,636 F1 · kind: Shares awarded are restricted stock units. The RSUs vest on the earlier of November 11, 2021, or the annual shareholders meeting in the year following the grant date. Read SEC document |
| November 19, 2020 Filed Dec 1, 2020 01:21 UTC Amendment |
Burt CarolDirector
|
GrantResMed Common Stock | 1,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-030144 · form4a.xml · nonDerivative · entry 1 Burt Carol · CIK 0001493926 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,187 F1 · balance_after: Corrects direct holdings for transfer of 1,727 shares to indirect holdings on November 23, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.